Phase I
Syndax Pharmaceuticals announced its treatment for mixed-lineage leukemia demonstrated robust clinical activity in a Phase I/II study.
Humanigen reported positive data from its Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL).
Please check out the biopharma industry’s COVID-19 stories that are trending for April 20, 2021.
It was a particularly busy week for clinical trial news, in part because of several big medical conferences. Here’s a look.
Shares of Inovio are climbing in early trading this morning after the company announced its DNA vaccine candidate for COVID-19 induced a robust T-cell response against multiple variants of the SARS-CoV-2 virus.
Please check out the biopharma industry’s COVID-19 stories that are trending for April 13, 2021.
Clinical-stage biotech company Celcuity announced Thursday that it had entered into a global licensing agreement with Pfizer to develop and commercialize gedatolisib, the latter company’s first-in-class PI3K/mTOR inhibitor for the treatment of breast cancer.
It was a relatively quiet week for clinical trial announcements, but there were a few standouts. Read on for more.
It was a busy week for clinical trial news. Here’s a look.
Days after announcing the U.S. Food and Drug Administration (FDA) has cleared the next clinical trials to launch for its lead natural killer (NK) cell therapies, NKMax America announced it has renamed itself NKGen Biotech.
PRESS RELEASES